Edward is Managing Partner and co-founder of BGV. Edward gained industry experience in product development and corporate licensing at Chiron and Johnson & Johnson. Since 2000 he expanded his experience as CEO of several life sciences companies. He currently serves on the supervisory boards of Azafaros, Scenic Biotech, Confo Therapeutics and TigaTx. He previously served on the supervisory boards of Progentix Orthobiology (acquired by Nuvasive ), Noviogendix (acquired by MDxHealth), was founding investor and supervisory board member of Acerta Pharma (acquired by Astra Zeneca) and was supervisory board member at Synaffix (acquired by Lonza). Edward is also on the board of Mibiton.

Edward holds a M.Sc. in Biochemistry from the University of Utrecht and a M.Sc in Biochemical Engineering from the Delft University of Technology.